Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Understanding Immune Response in Non–Small Cell Lung Cancer

October 26th 2020

Patient Selection: Adjuvant Therapy and Testing for ES NSCLC

October 26th 2020

Phase 3 ADAURA Study: EGFR-Mutated NSCLC

October 26th 2020

Chemotherapy and Immunotherapy in Non–Small Cell Lung Cancer

October 26th 2020

Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer

October 26th 2020

Role of Postoperative Radiotherapy in Early Stage NSCLC

October 26th 2020

Neoadjuvant Chemotherapy in Early-Stage NSCLC

October 26th 2020

Treatment Efficacy in Non–Small Cell Lung Cancer

October 26th 2020

Treatment of Early-Stage NSCLC: Current Standard of Care

October 26th 2020

Frontline Treatment in Non–Small Cell Lung Cancer

October 26th 2020

Immunotherapy Combos Continue to Excel in NSCLC, But Patient Selection Must Be Optimized

October 23rd 2020

In an interview with OncLive® Michael Shafique, MD, discusses examples of this groundbreaking research of immunotherapy combinations in NSCLC.

Afatinib Efficacious in EGFR+ NSCLC Harboring Major Uncommon Mutations, Irrespective of Ethnicity

October 23rd 2020

Afatinib was found to be effective when used in Asian and non-Asian patients with non–small cell lung cancer with major uncommon and compound EGFR mutations, irrespective of ethnicity.

Evaluating New Standards in Extensive-Stage Small Cell Lung Cancer

October 23rd 2020

Igor I. Rybkin, MD, PhD, discusses the data with these frontline and second-line regimens in extensive-stage small cell lung cancer.

Subbiah Addresses Controversy Surrounding Pembrolizumab Approval for TMB-High Tumors

October 22nd 2020

In a special episode of OncLive On AirTM Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in TMB-high solid tumors and addressed the controversy surrounding the approval.

Real World Data Show Afatinib as Effective, Safe in Second-Line Metastatic Squamous Lung Cancer

October 21st 2020

Afatinib was found to be effective and well tolerated when used as a second-line treatment in patients with metastatic squamous carcinoma of the lung.

FDA Grants Priority Review to Adjuvant Osimertinib for Early-Stage EGFR+ Lung Cancer

October 20th 2020

The FDA has granted osimertinib a priority review designation to a supplemental new drug application for the adjuvant treatment of patients with early-stage EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

PLCOm2012 Risk Prediction Model Is Highly Sensitive in Identifying African American Ever-Smokers With Lung Cancer

October 20th 2020

The PLCOm2012 risk prediction model is a preferable lung cancer screening method for identifying African American ever-smokers over the current United States Preventive Services Task Force lung cancer screening eligibility criteria, which may help to overcome racial disparities.

Paradigm Shift for Early EGFR+ NSCLC

October 20th 2020

Practical Implications of ADAURA in NSCLC

October 20th 2020

Unprecedented Results from ADAURA

October 20th 2020